Skip to main content

Table 1 Baseline characteristics of patients on opioid agonist therapy in Norway

From: Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017

Baseline characteristics

2013

2014

2015

2016

2017

No.

%

No.

%

No.

%

No.

%

No.

%

Patients

7709

 

7914

 

7958

 

7804

 

7709

 

Deaths

165

 

151

 

138

 

114

 

124

 

Patients, excl. deaths

7544

 

7763

 

7820

 

7690

 

7585

 

Age

 - ≤ 25

211

3

185

2

171

2

135

2

120

2

 - 26-35

1590

21

1570

20

1551

20

1403

18

1333

18

 - 36-45

2724

36

2730

35

2605

33

2508

33

3292

32

 - 46-55

2283

30

2449

32

2544

33

2540

33

2548

34

 - ≥ 56

736

10

829

11

949

12

1104

14

1192

16

Mean (SD)

43 (10)

44 (10)

44 (10)

44 (10)

45 (10)

Gender

 Men

5221

69

5390

69

5430

69

5354

70

5245

69

 Women

2323

31

2373

31

2390

31

2336

30

2340

31

OAT opioidsa

 Methadone, included levomethadone

3406

45

3264

42

3216

41

3066

40

2981

39

 Buprenorphineb

4138

55

4499

58

4604

59

4624

60

4604

61

Potentially addictive drugs

 Dispensed a benzodiazepine and z-hypnoticc

3747

50

3809

49

3714

47

3758

49

3762

50

 Dispensed a gabapentinoid

708

9

662

9

717

9

762

10

845

11

  1. NorPD Norwegian Prescription Database, OAT Opioid agonist therapy, SD Standard deviation
  2. aThe last type of dispensed OAT opioid per year
  3. bInclude buprenorphine-naloxone
  4. cZ-hypnotic includes zolpiclone and zolpidem